Key facts
- This page summarizes George Craig Shapiro's Form 4 filing for Zeo ScientifiX, Inc. (ZEOX).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 16 Jan 2026, 16:05.
George Craig Shapiro - 14 Jan 2026 Form 4 Insider Report for Zeo ScientifiX, Inc. (ZEOX)
- Reporting relationship
- Chief Medical Officer, Director
- Issuer ticker
- ZEOX
- Reported as of
- 14 Jan 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 16 Jan 2026, 16:05:12 UTC
- Prior SEC filing
- 12 May 2025
- Next SEC filing
- 12 Jun 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ George Craig Shapiro
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
George Craig Shapiro filed Form 4 for Zeo ScientifiX, Inc. (ZEOX) on 16 Jan 2026.
Change
- Previous filing in this sequence was filed on 12 May 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001804141
Primary reporting owner
Shapiro George Craig
- Relationship
- Chief Medical Officer, Director
- Address
- 3321 COLLEGE AVENUE, SUITE 246, DAVIE
- Signature
- /s/ George Craig Shapiro
- Signature date
- 16 Jan 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ZEOX
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +175,000
- Change %
- +43%
- Price
- $0.000000
- Shares after
- 578,021
- Date
- 14 Jan 2026
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Represents the grant of restricted shares of the Issuer's common stock under its 2021 Equity Incentive Plan (the "2021 Plan"). The shares vest 50% on the 8th month anniversary of the grant date and the remaining 50% on the 12th month anniversary.